Willow Biosciences (CSE: WLLW) (OTCQB: CANSF) on Tuesday announced its receipt of final approval to list its common shares on the Toronto Stock Exchange (the “TSX”). According to the update, Willow’s common shares will commence trading on the TSX effective as of the open of the market on Thursday, December 5, 2019. The common shares … Continue reading “NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) to Commence Trading on the Toronto Stock Exchange on December 5”
Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF), a Canadian biotechnology company and a leading developer in biosynthetically produced cannabidiol (“CBD”), this morning issued a release commenting on the recent news that the U.S. Drug Enforcement Agency (“DEA”) has removed Purisys, LLC’s CBD from Schedule I of the Controlled Substances Act (“CSA”). Purisys, the spin-out entity … Continue reading “NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Comments on DEA Descheduling Partner’s CBD”
Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) today announced its receipt of conditional approval from the Toronto Stock Exchange (the “TSX”) to list its common shares on the TSX. According to the update, final approval of the listing is subject to Willow Biosciences meeting certain TSX customary conditions, and Willow will issue a statement upon … Continue reading “NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Announces Receipt of Conditional Approval to List on the Toronto Stock Exchange”
Willow Biosciences (CSE: WLLW) (OTCQB: CANSF) on Thursday announced its financial and operating results for the three and nine months ended September 30, 2019. Among other highlights, the company reported that it ended the quarter with around $23.2 million of working capital and $24 million of cash on hand. Willow’s unaudited condensed consolidated interim financial … Continue reading “NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Posts Q3 2019 Financial Results, Operations Update”
Willow’s plan to provide biosynthetic cannabinoid has potential to disrupt the cannabis-industry supply chain Biosynthetically derived cannabinoids offer unique advantages related to reliability, scalability, quality and cost Key collaboration allows company to capitalize on enormous market opportunity Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF), an emerging biotechnology company focused on the biosynthetic production of cannabinoids, … Continue reading “Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Eyes Opportunity to Provide Biosynthetic Cannabinoids in Market with Explosive Potential”
Willow Biosciences (CSE: WLLW) (OTCQB: CANSF) today announced its plans to participate in the Cowen 2nd Annual Boston Cannabis Conference, a carefully curated event to represent leading-edge companies across a wide array of products, brands, technologies, services and health care providers in the emerging cannabis industry. According to the update, the event is scheduled to … Continue reading “NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Announces Plans to Participate in Cowen 2nd Annual Boston Cannabis Conference”
Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) today announced that it has been approved to commence trading on the OTCQB® Venture Market (the “OTCQB”), under the symbol “CANSF,” beginning today, November 5, 2019. The listing will enable Willow Biosciences access to a broader base of U.S. and international retail and institutional investors, ultimately providing increased … Continue reading “NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) to Begin Trading on the OTCQB® Venture Market”
Willow Biosciences Inc. (CSE: WLLW) today announced its plans to participate at the Eight Capital & Cassels Brock Global Cannabis Conference slated to be held at the Shangri-La Hotel in Toronto on September 19, 2019. Willow Biosciences will be available for one-on-one meetings during the event. In addition, Willow CEO, President and Director Trevor Peters … Continue reading “NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Announces Plans to Participate at the Eight Capital & Cassels Brock Global Cannabis Conference”
Willow Biosciences (CSE: WLLW), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, was recently covered in a research report by Eight Capital. Per the report, Eight Capital issued a ‘Buy’ rating and a target price of $4.50 for WLLW, determined in part by Willow’s chosen method of … Continue reading “NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Highlighted in Comprehensive Research Report”
Willow Biosciences Inc. (CSE: WLLW) on Tuesday announced that it has granted an aggregate of 1,118,000 stock options for certain employees to purchase common shares of Willow pursuant to the terms and conditions of its stock option plan. According to the update, the options expire five years from the grant date, are exercisable at a … Continue reading “NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Announces Stock Option Grant and Unit Issuance”
